Pharma and Biopharma Outsourcing Solutions from Intertek
Intertek‘s expert pharmaceutical analysis, auditing and regulatory services are helping clients to save costs. Successful innovative, tailored programmes for biologics and pharmaceuticals can be applied to product / clinical development and manufacturing. ICSE, Stand 10E89.
Pharma and Biopharma Outsourcing Solutions from Intertek
Intertek, a leading provider of Pharmaceutical Services will highlight how its unique blend of expert pharmaceutical & biopharmaceutical analysis, auditing and regulatory services are helping to save the industry material costs whilst raising the safety of its products and reliability of its supply chains at ICSE / CPhi, Madrid, Spain, 9-11 October 2012. Stand 10E89.
In particular Intertek’s service offering for biologics will be a key focus area. With the annual sales of biologic drugs forecast to grow up to three times faster than conventional drugs over the next 5 years Intertek’s strategy has been to establish a “one stop” analytical shop specifically relating to the requirements of ICH Q6B. The team, based in UK, Ireland, Basel and Sand Diego specializes in the design and delivery of regulatory (GXP) studies relating to the physiochemical and biological activity of biomolecules, bioanalytical support and manufacturing troubleshooting.
Experts from Intertek Pharmaceutical Services will be available during ICSE to share the experience of its history of successful innovative and tailored programmes. Covering a wide scope of services for both clinical development and product testing, such as GLP bioanalysis, GMP product analysis, auditing, method development validation and remediation, GMP microbiology, manufacturing technical support or sustainability consultancy, Intertek experts will be engaging on clients’ outsourcing needs for the year ahead and beyond.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
